Brief: Adicet Bio Q4 Basic EPS USD -0.69
19/03/2024 20:10
Mar 19 (Reuters) - Adicet Bio Q4 net income USD -29.489 million vs. IBES estimate USD -30.4 million. * Q4 operating income USD -31.566 million vs. IBES estimate USD -32 million * Q4 operating expenses USD 31.566 million
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary